- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Emerging Bispecifics in Multiple Myeloma: Real-World Insights and Treatment Strategies
Robert M. Rifkin, MD, FACP, discusses how findings from real-world studies on teclistamab and talquetamab presented at the 66th American Society of Hematology Annual Meeting and Exposition reinforce their efficacy and impact on patient outcomes in relapsed/refractory multiple myeloma while panelists discuss how clinicians should prioritize factors such as patient characteristics and treatment history when selecting the most appropriate bispecific therapy for these patients.
EP: 1.Emerging Bispecifics in Multiple Myeloma: Real-World Insights and Treatment Strategies
EP: 2.Navigating Adverse Events in Bispecific Antibody Therapies: Infection Prevention and Management
EP: 3.Proactive CRS Management: The Role of Tocilizumab and Beyond
EP: 4.Expanding Bispecific Therapies to Community Settings: Challenges and Innovations
EP: 5.Leveraging Telehealth and Collaboration for Rural and Community Care Expansion
EP: 6.Streamlining Transitions Between Academic and Community Centers
EP: 7.Optimizing Care Models for Bispecific Antibodies: Strategies for Cost-Effective Delivery
Video content above is prompted by the following:
- Findings from real-world studies on teclistamab and talquetamab presented at 66th American Society of Hematology Annual Meeting and Exposition highlighted their efficacy and patient outcomes outside clinical trials. How do these findings align with clinical trial data, and what differences (if any) stand out to you in the real-world setting?
- Based on the real-world evidence shared for teclistamab and talquetamab, what factors should clinicians prioritize when selecting the appropriate bispecific therapy for patients with relapsed/refractory multiple myeloma?
Early Data Show Promising Outcomes as CAR T-Cell Therapy Expands Beyond Academic Centers
January 12th 2026Abstracts presented at ASH 2025 explore CAR T-cell therapy's effectiveness in newly authorized treatment centers, revealing promising outcomes for multiple myeloma patients and the prospect of expanded access.
Read More
